ILUMYA

This brand name is authorized in United States. It is also authorized in Australia, Israel, Japan.

Active ingredients

The drug ILUMYA contains one active pharmaceutical ingredient (API):

1	Tildrakizumab UNII DEW6X41BEK - TILDRAKIZUMAB
	Tildrakizumab is a humanized IgG1/k monoclonal antibody that specifically binds to the p19 protein subunit of the interleukin-23 (IL-23) cytokine without binding to IL-12 and inhibits its interaction with the IL-23 receptor. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.
	Read more about Tildrakizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ILUMYA Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AC17		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC17

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11613F, 11616J
IL	מִשְׂרַד הַבְּרִיאוּת	8772
JP	医薬品医療機器総合機構	3999456G1025
US	FDA, National Drug Code	47335-177